Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management

References

• BoneHGHoskingDDevogelaerJPTen years’ experience with alendronate for osteoporosis in postmenopausal women. Alendronate Phase III Osteoporosis Treatment Study GroupN Engl J Med2004350121189119915028823
   PubMed Web of Science ®Google Scholar
• McClungMRWasnichRDReckerROral Ibandronate Study Group. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosisJ Bone Miner Res2004191111814753731
   PubMed Web of Science ®Google Scholar
• Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trialJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• BoonenSAutierPBaretteMVanderschuerenDLipsPHaentjensPFunctional outcome and quality of life following hip fracture in elderly women: A one-year prospective controlled studyOsteoporos Int2004152879414605799
   PubMed Web of Science ®Google Scholar
• RogersMJNew insight into molecular mechanism of action of bisphosphonateCurr Pharm Res200392326432658
   Google Scholar
• CramerJAAmonkarMMHebbornAAltmanRCompliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin20052191453146016197664
   PubMed Web of Science ®Google Scholar
• HuybrechtsKFIshakKJCaroJJAssessment of compliance with osteoporosis treatment and its consequences in a managed care populationBone200663892292816330270
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosis: HORIZON Pivotal Fracture TrialN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• ReidIRBrownJPBurckhardtPIntravenous zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med2002346965366111870242
   PubMed Web of Science ®Google Scholar
• FleishHBone and mineral metabolismBisphosphonates in Bone DiseasesSan Diego, CAAcademic Press2000
   Google Scholar
• LinJHChenIWDelunaFARenal handling of alendronate in rats. An uncharacterized renal transport systemDrug Metab Dispos19922046086131356743
   PubMed Web of Science ®Google Scholar
• RussellRGGWattsNBEbetinoFHRogersMJMechanism of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacyOsteoporos Int200819673375918214569
   PubMed Web of Science ®Google Scholar
• FleishHBisphosphonates: Mechanism of actionEndocrine Rev1998191801009494781
   PubMed Web of Science ®Google Scholar
• GertzBJHollandSDKlineWFStudies of the oral bioavailability of AlendronateClin Pharmacol Ther19955832882987554702
   PubMed Web of Science ®Google Scholar
• Pedersen-BjergaardUMyhreJSevere hypocalcaemia after treatment with diphosphonate and aminoglycosideBMJ199130267712951825614
   PubMed Web of Science ®Google Scholar
• SatoMGrasserWEndoNBisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructureJ Clin Invest1991688209521051661297
   PubMed Web of Science ®Google Scholar
• SaloJLehenkariPMulariMRemoval of osteoclast bone resorption products by transcytosisScience199753102762702739092479
   PubMed Web of Science ®Google Scholar
• RogersMJFrithJCLuckmanSPMolecular mechanisms of action of bisphosphonatesBone199924Suppl 573S79S10321934
   PubMed Web of Science ®Google Scholar
• GreenJRBisphosphonates: Preclinical reviewOncologist20049Suppl 4S3S13
   PubMed Web of Science ®Google Scholar
• VitteCFleischHGuentherHLBisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast mediated resorptionEndocrinology19961376232423338641182
   PubMed Web of Science ®Google Scholar
• StormTSteinichwTThamsborgGChanges in bone histomorphometry after long-term treatment with intermittent cyclic etidronate for postmenopausal osteoporosisJ Bone Miner Res1993821992088442438
   PubMed Web of Science ®Google Scholar
• EbertRZeckSKrugRPulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiationBone200944585886419442618
   PubMed Web of Science ®Google Scholar
• Von KnochFJaquieryCKowalskyMEffects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cellsBiomaterials200526346941694916009417
   PubMed Web of Science ®Google Scholar
• PlotkinLIWeinsteinRSParfittAMPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitoninJ Clin Invest1999104101363137410562298
   PubMed Web of Science ®Google Scholar
• GiulianiNPedrazzoniMNegriGBisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivoBone19982254554619600778
   PubMed Web of Science ®Google Scholar
• MundyGGarretRHarrisSStimulation of bone formation in vitro and in rodent by statinsScience199928654461946194910583956
   PubMed Web of Science ®Google Scholar
• ViereckVEmonsGLauckVBisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblastsBiochem Biophys Res Comm2002291368068611855844
   PubMed Web of Science ®Google Scholar
• ScuttABertramPBräutigamMThe role of glucocorticoid and prostaglandins E2 in the recruitment of bone marrow mesenchymal cells to the osteoblastic lineage: Positive and negative effectsCalcif Tissue Int19965931541628694891
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insight into actions of bisphosphonates on bone: Differences in interactions with hydroxy-apatiteBone200638561762716046206
   PubMed Web of Science ®Google Scholar
• WidlerLJaeggiKAGlattMHighly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)J Med Chem200245173721373812166945
   PubMed Web of Science ®Google Scholar
• KavanaghKLGuoKDunfordJEThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProc Natl Acad Sci U S A2006103207829783416684881
   PubMed Web of Science ®Google Scholar
• LinJHBisphosphonates: A review of their pharmacokinetic propertiesBone199618275858833200
   PubMed Web of Science ®Google Scholar
• CremersSCPillaiGPapapoulosSEPharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosisClin Pharmacokinet200544655157015932344
   PubMed Web of Science ®Google Scholar
• Aclasta LeafletPharmacological properties – Pharmacokinetic properties Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/aclasta/emea-combined-h595en.pdf. Accessed Apr 16, 2010.
   Google Scholar
• PaganiFFrancucciCMMoroLMarkers of bone turnover: Biochemical and clinical perspectivesJ Endocrinol Invest200528Suppl 10S8S13
   Google Scholar
• MeltonLJIIIKhoslaSAtkinsonEJO’FallonWMRiggsBLRelationship of bone turnover to bone density and fracturesJ Bone Miner Res1997127108310919200008
   PubMed Web of Science ®Google Scholar
• SchettGKiechlSRedlichKSoluble RANKL and risk of nontraumatic fractureJAMA200429191108111314996780
   PubMed Web of Science ®Google Scholar
• Dalle CarbonareLValentiMTZanattaMDonatelliLLo CascioVCirculating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosisArthritis Rheum200960113356336519877060
   PubMed Web of Science ®Google Scholar
• EastellRBartonIHannonRAChinesAGarneroPDelmasPDRelationship of early changes in bone resorption to the reduction in fracture risk with risedronateJ Bone Miner Res20031861051105612817758
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging200012111210746426
   PubMedGoogle Scholar
• BrownJPKendlerDLMcClungMRThe efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int2002271103111
   PubMed Web of Science ®Google Scholar
• ReginsterJYAdamiSLakatosPEfficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: Two year results from the MOBILE studyAnn Rheum Dis200665565466116339289
   PubMed Web of Science ®Google Scholar
• MellstromDDSörensenOHGoemaereSRouxCJohnsonTDChinesAASeven years of treatment with risedronate in women with postmenopausal osteoporosisCalcif Tissue Int200475646246815455188
   PubMed Web of Science ®Google Scholar
• WattsNBChinesAOlszysnkiWPFracture risk remains reduced one year after discontinuation of risedronateOsteoporos Int20081936517938986
   PubMed Web of Science ®Google Scholar
• ReidDMDevogelaerJPSaagKZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trialLancet2009373111253126319362675
   PubMed Web of Science ®Google Scholar
• McClungMMillerPRecknorCZoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: A randomized controlled trialObstet Gynecol20091145999100720168099
   PubMed Web of Science ®Google Scholar
• MarxRECilloJEUlloaJJOral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention and treatmentJ Oral Maxillofac Surg200765122397241018022461
   PubMed Web of Science ®Google Scholar
• BedogniABlandamuraSLokmicZBisphosphonate-associated jawbone osteonecrosis: A correlation between imaging techniques and histopathologyOral Surg Oral Med Oral Pathol Oral Radiol Endod2008105335836418280968
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women. Relationship to vertebral and non vertebral fractures from 2 US Claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• TostesonANGroveMRHammondCSEarly discontinuation of treatment for osteoporosisAm J Med2003115320921612947959
   PubMed Web of Science ®Google Scholar
• SeemanECompstonJAdachiJNon-compliance: The Achilles’ heel of antifracture efficacyOsteoporos Int200761871171917245547
   PubMed Web of Science ®Google Scholar
• HamiltonBMcCoyKTaggartHTolerability and compliance with risedronate in clinical practiceOsteoporos Int200314325926212730745
   PubMed Web of Science ®Google Scholar
• de GroenPCLubbeDFHirschLJEsophagitis associated with the use of alendronateN Engl J Med199633514101610218793925
   PubMed Web of Science ®Google Scholar
• RosenCJHochbergMCBonnickSLTreatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind studyJ Bone Miner Res200520114115115619680
   PubMed Web of Science ®Google Scholar
• BobbaRSBeattieKParkinsonBKumbhareDAdachiJDTolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone diseaseDrug Saf200629121133115217147460
   PubMed Web of Science ®Google Scholar
• HewittRELissinaAGreenAESlayESPriceDASewellAKThe bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsClin Exp Immunol200539110111115606619
   PubMed Web of Science ®Google Scholar
• CaccamoNMeravigliaSScarpaFAminobisphosphonate activated gammadelta T cells in immunotherapy of cancer: Doubts no moreExpert Opin Biol Ther20088787588318549319
   PubMed Web of Science ®Google Scholar
• BertoldoFPancheriSZenariSSerum 25(OH)D level modulate the acute phase response associated to the first nitrogen containing bisphosphonate infusionJ Bone Miner Res200925344745420200999
   PubMed Web of Science ®Google Scholar
• LüheAKünkeleKPHaikerMPreclinical evidence for nitrogen containing bisphosphonate inhibition of farnesyl biphosphonate (FPP) synthase in the kidney: Implications for renal safetyToxicology in Vitro200822489990918325729
   PubMed Web of Science ®Google Scholar
• BoonenSVanderschuerenDVenkenKRecent developments in the management of postmenopausal osteoporosis with bisphosphonates: Enhanced efficacy by enhanced complianceJ Intern Med2008264431533218823505
   PubMed Web of Science ®Google Scholar
• ContePFGuarnieriVSafety of intravenous and oral bisphosphonates and compliance with dosing regimensOncologist20049Suppl 4283715459427
   PubMed Web of Science ®Google Scholar
• ChenTBerensonJVescioRPharmacokinetics and pharmaco-dynamics of zoledronic acid in cancer patients with bone metastasesJ Clin Pharmacol20024311154162
   Google Scholar
• SkerjanecCBerensonJHsuCMajorPThe pharmacokinetics and pharmacodynamics in cancer patients with varying degrees of renal functionJ Clin Pharmacol20034221228123612412821
   PubMed Web of Science ®Google Scholar
• CummingsSRSchwartzAVBlackDMAlendronate and atrial fibrillationN Engl J Med2007356181895189617476024
   PubMed Web of Science ®Google Scholar
• AvilesRJMartinDOApperson-HansenCInflammation as a risk factor for atrial fibrillationCirculation2003108243006301014623805
   PubMed Web of Science ®Google Scholar
• Van WagonerDRNerbonneJMMolecular basis of electrical remodeling in atrial fibrillationJ Mol Cell Cardiol20003261101111710888261
   PubMed Web of Science ®Google Scholar
• PazianasMichaelCompstonJulietHuangChristopher L-HAtrial fibrillation and bisphosphonate therapyJ Bone Miner Res201025121020091928
   PubMed Web of Science ®Google Scholar
• HarrisSTGertzBJGenantHKThe effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal womenJ Clin Endocrinol Metab1993766139914068501142
   PubMed Web of Science ®Google Scholar
• ChesnutCH3rdHarrisSTShort-term effect of alendronate on bone mass and bone remodeling in postmenopausal womenOsteoporos Int19933Suppl 3S17S198298198
   PubMed Web of Science ®Google Scholar
• ChennuruSKoduriJBaumanMARisk factors for symptomatic hypocalcemia complicating treatment with zoledronic acidIntern Med J200838863563718284458
   PubMed Web of Science ®Google Scholar
• TanvetyanonTStiffPJManagement of the adverse effects associated with intravenous bisphosphonatesAnn Oncol200617689790716547070
   PubMed Web of Science ®Google Scholar
• FraunfelderFWFraunfelderFTJensvoldBScleritis and other ocular side effects associated with pamidronate disodiumAm J Ophthalmol2003135221922212566027
   PubMed Web of Science ®Google Scholar
• FrenchDDMargoCEPostmarketing surveillance of uveitis and scleritis with bisphosphonates among a national veteran cohortRetina200828688989318536608
   PubMed Web of Science ®Google Scholar
• RyanPJSampathRIdiopathic orbital inflammation following intravenous pamidronateRheumatology20014095695711511778
   PubMed Web of Science ®Google Scholar
• OdvinaCVZerwekhJERaoDSMaaloufNGottschalkFAPakCYSeverely suppressed bone turnover: A potential complication of alendronate therapyJ Clin Endocrinol Metab20059031294130115598694
   PubMed Web of Science ®Google Scholar
• EdwardsMHMcCraeFCYoung-MinSAAlendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side?Osteoporos Int201021470170319562241
   PubMed Web of Science ®Google Scholar
• LenartBALorichDGLaneJMAtypical fractures of the femoral diaphysis in postmenopausal women taking alendronateN Engl J Med2008358121304130618354114
   PubMed Web of Science ®Google Scholar
• VisekrunaMWilsonDMcKienanFESeverely suppressed bone turnover and atypical skeletal fragilityJ Clin Endocrinol Metab20089382948295218522980
   PubMed Web of Science ®Google Scholar
• SalminenSPihlajamakiHAvikainenVSpecific features associated with femoral shaft fractures caused by low-energy traumaJ Trauma19974311171229253920
   PubMedGoogle Scholar
• BertoldoFSantiniDLo CascioVBisphosphonates and osteomyelitis of the jaw: A pathogenic puzzleNat Clin Pract Oncol200741271172118037875
   PubMedGoogle Scholar
• FelsembergDHoffmeisterBAmlingMOnkologie: Kiefernekrosen nach hoch dosierter BisphosphonattherapieDeutsches Arzteblatt200610330783081 German.
   Google Scholar
• SambrookPOlverIGossABisphosphonates and osteonecrosis of the jawAust Fam Physician2006351080180317019456
   PubMedGoogle Scholar
• GrbicJTLandesbergRLinSQIncidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trialJ Am Dent Assoc20081391324018167382
   PubMed Web of Science ®Google Scholar
• ReckerRRDelmasPDHalseJEffects of intravenous zoledronic acid once yearly on bone remodeling and bone structureJ Bone Miner Res200823161617892374
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJBisphosphonates-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. ASBMR Task Force on Bisphosphonate-Associated ONJJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• ReidIROsteonecrosis of the jaw – Who gets it, and whyBone200944141018948230
   PubMed Web of Science ®Google Scholar
• KhanAASándorGKDoreECanadian Association of Oral and Maxillofacial Surgeons. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jawJ Rheumatol20083571391139718528958
   PubMed Web of Science ®Google Scholar
• NovinceCMWardBBMcCauleyLKOsteonecrosis of the jaw: An update and review of recommendationsCells Tissues Organs20091891–427528318765930
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• ReckerRLipsPFelsenbergDAlendronate with and without cholecalciferol for osteoporosis: Results of a 15-week randomized controlled trialCurr Med Res Opin20062291745175516968578
   PubMed Web of Science ®Google Scholar
• BinkleyNRingeJDReedJIAlendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trialBone200944463964719185560
   PubMed Web of Science ®Google Scholar
• DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone2008421364217920005
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupJAMA1999282111344135210527181
   PubMed Web of Science ®Google Scholar
• AdachiJDSaagKGDelmasPDTwo-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trialArthritis Rheum200144120221111212161
   PubMed Web of Science ®Google Scholar
• WallachSCohenSReidDMEffects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapyCalcif Tissue Int200067427728511000340
   PubMed Web of Science ®Google Scholar
• OrwollEEttingerMWeissSAlendronate for the treatment of osteoporosis in menN Engl J Med2000343960461010979796
   PubMed Web of Science ®Google Scholar
• BoonenSOrwollESWenderothDOnce-weekly risedronate in men with osteoporosis: Results of a 2-year, placebo-controlled, double-blind, multicenter studyJ Bone Miner Res200924471972519049326
   PubMed Web of Science ®Google Scholar
• ChestnutCHIIISkagAChristiansenCOral Ibandronate vertebral fracture trial in Norrth America and Europe (BONE) Effect of oral ibandronate administered daily or intermittently on racture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
   PubMed Web of Science ®Google Scholar
• RiisBJIseJvon SteinTIbandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosisJ Bone Miner Res200116101871187811585352
   PubMed Web of Science ®Google Scholar
• DevogelaerJPBrownJPBurckhardtPZoledronic acid efficacy and safety over five years in postmenopausal osteoporosisOsteoporos Int20071891211121817516022
   PubMed Web of Science ®Google Scholar
• BauerDCBlackDMGarneroPChange in bone turnover and hip, non spine and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial Study GroupJ Bone Miner Res20041981250125815231011
   PubMed Web of Science ®Google Scholar
• LylesKWColón-EmericCSMagazinerJSfor the HORIZON Recurrent Fracture TrialZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone200741112212817468062
   PubMed Web of Science ®Google Scholar
• ReidDMDevogelaerJPSaagKZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trialLancet2009373111253126319362675
   PubMed Web of Science ®Google Scholar
• Van StaaTPThe pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosisCalcif Tissue Int200637912913716969593
   PubMed Web of Science ®Google Scholar
• JonesGNguyenTSambrookPNSymptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES)Osteoporosis Int199445277282
   PubMed Web of Science ®Google Scholar
• LeibsonCLTostesonANGabrielSEMortality, disability, and nursing home use for persons with and without hip fracture: A population-based studyJ Am Geriatr Soc200250101644165012366617
   PubMed Web of Science ®Google Scholar
• Breast International Group (BIG) 1-98 Collaborative GroupA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• ForwardDPCheungKLJacksonLRobertsonJFClinical and endocrine data for goserelin plus anastrozole as secondline endocrine therapy for premenopausal advanced breast cancerBr J Cancer200490359059414760369
   PubMed Web of Science ®Google Scholar
• ATAC Trialists’ GroupEffect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)J Bone Miner Res20062181215122316869719
   PubMed Web of Science ®Google Scholar
• BundredNJCampbellIDDavidsonNEffective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study resultsCancer200811251001101018205185
   PubMed Web of Science ®Google Scholar
• BrufskyABossermanLCaradonnaRThe effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The Z-FAST study 36-month follow-upProceedings of the 30th Annual San Antonio Breast Cancer SymposiumSan Antonio, TX2007 Dec 13–16
   Google Scholar
• RossRSmallEOsteoporosis in men treated with androgen deprivation therapy for prostate cancerJ Urol200216751952195611956415
   PubMed Web of Science ®Google Scholar
• RyanCWHuoDDemersLMBeerTMLacernaLVZoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancerJ Urol2006176397297816890673
   PubMed Web of Science ®Google Scholar
• SmithMREasthamJGleasonDMRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerJ Urol200316962008201212771706
   PubMed Web of Science ®Google Scholar
• BrownTTQaqishRBAntiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic reviewAIDS200620172165217417086056
   PubMed Web of Science ®Google Scholar
• BollandMJGreyABHorneAMAnnual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: A randomized controlled trialJ Clin Endocrinol Metab20079241283128817227801
   PubMed Web of Science ®Google Scholar
• GianniniSD’AngeloACarraroGAlendronate prevents further bone loss in renal transplant recipientsJ Bone Miner Res200116112111211711697808
   PubMed Web of Science ®Google Scholar
• ShaneEAddessoVNamerowPBAlendronate versus calcitriol for the prevention of bone loss after cardiac transplantationN Engl J Med20043502276777614973216
   PubMed Web of Science ®Google Scholar
• CrawfordBAKamCPavlovicJZoledronic acid prevents bone loss after liver transplantation: A randomized, double-blind, placebo-controlled trialAnn Intern Med2006144423924816490909
   PubMed Web of Science ®Google Scholar
• SirisESSelbyPLSaagKGImpact of osteoporosis treatment adherence on fracture rates in North America and EuropeAm J Med2009122Suppl 2S3S1319187810
   PubMed Web of Science ®Google Scholar
• GoldDTMartinBCFrytakJRA claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosisCurr Med Res Opin200723358559417355739
   PubMed Web of Science ®Google Scholar
• CooperADrakeJBrankinETreatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: Results from the PERSIST studyInt J Clin Pract200660889690516800837
   PubMed Web of Science ®Google Scholar
• SaagKLindsayRKriegmanAA single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBone20074051238124317347063
   PubMed Web of Science ®Google Scholar